Wire · opportunities
Roche receives FDA clearance for Elecsys® pTau217, advancing Alzheimer's disease ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 24 August 2026 · Fusion42 review
Roche has received FDA clearance for Elecsys pTau217, the first and only FDA-cleared single-biomarker blood test that supports both rule-in and rule-out assessment of amyloid pathology related to Alzheimer's disease across primary and specialty care in the U.S. The test leverages Roche's existing U.S. lab infrastructure, enabling broad clinical adoption to aid earlier and easier diagnosis.
This Wire brief sits within Fusion42's coverage of Medtech, and 6 sources have reported it between 24 Aug 2026 and 26 Aug 2026.
◆ ◆ The Wire takeaway
You can now offer the only FDA-cleared single-test blood assay for amyloid pathology in Alzheimer's, letting you move diagnostic assessment out of specialist settings and into primary care with ease. This opens access to more patients earlier and creates new pathways for your diagnostic and care services.
◆ Coverage
6 sources · first reported 24 Aug 2026 · latest 26 Aug 2026
◆ Related on Wire
◆ Topics